Add Row
Add Element
Glytain Logo
update
Glytain.com
update
Add Element
  • Home
  • Categories
    • Healthcare
    • Innovation
    • Digital
    • Marketing
    • Analysis
    • Insights
    • Trends
    • Empowerment
    • Providers
    • Tech News
    • Extra News
Add Row
Add Element
March 14.2025
2 Minutes Read

How a Breast Cancer Survivor is Changing Chemotherapy with Privacy & Innovation

Woman in headscarf looking out window, related to scalp cooling therapy.

A Revolutionary Approach to Chemotherapy Care

Kate Dilligan, a breast cancer survivor, understands the emotional toll of chemotherapy. Hair loss is one of the most visible and distressing side effects, leading many patients to forgo this potentially life-saving treatment. Her company, Cooler Heads, aims to change that narrative. By offering a portable cooling device that enables patients to retain their hair during treatments, Dilligan combines her personal experiences with innovative healthcare solutions.

Understanding the Impact of Hair Loss on Patients

Approximately 8% of cancer patients refuse chemotherapy primarily due to the fear of losing their hair. This seemingly cosmetic issue often correlates with a significant loss of privacy and self-esteem. As Dilligan explains, walking into public spaces while undergoing cancer treatment can expose patients to unwanted attention simply because of their appearance. Protecting privacy is not about vanity—it’s about maintaining one’s dignity during a challenging health battle.

The Science Behind Scalp Cooling Therapy

Scalp cooling involves medically induced hypothermia targeting hair follicles to minimize hair loss during chemotherapy. Traditional gels and caps have been cumbersome, often requiring assistance during painful and exhausting treatments. Cooler Heads’ device, however, promotes patient independence; weighing just 23 pounds and designed for portable use, it allows patients to engage in their normal lives, even during treatment.

Taking Control: A Patient Empowerment Story

Dilligan’s own journey through chemotherapy prompted her to create a solution when her own scalp cooling assistant quit on short notice, leaving her feeling powerless. Her experience underscored the necessity for more patient control in chemotherapy—a theme embedded in the mission of Cooler Heads. The device not only helps retain hair but also symbolizes empowerment and choice for cancer patients.

The Market and Future Outlook for Scalp Cooling Solutions

With the FDA clearance obtained in 2021, Cooler Heads has been gradually adopted across 23 states, representing a shift in how healthcare providers approach the sensitive issue of hair loss during treatment. The device alleviates the burden of traditional cooling methods, enhancing patient experience and providing a new avenue for healthcare systems to improve service delivery.

In a landscape where privacy and emotional well-being can significantly influence treatment choices, Dilligan’s Cooler Heads not only promotes aesthetic retention but fosters a culture of respect and dignity for those navigating cancer treatment.

Stay tuned for more innovations in patient care as startups like Cooler Heads redefine the cancer journey, helping patients reclaim their confidence one treatment at a time.

Healthcare

Write A Comment

*
*
Related Posts All Posts

Explore Lipoprotein (a): Understanding Its Role in Cardiovascular Risk

Update Understanding Lipoprotein (a) and Cardiovascular Risks When it comes to heart health, many of us are familiar with cholesterol, but have you heard about lipoprotein (a)? Dr. Vlad Vasile from Mayo Clinic sheds light on this crucial lipid blood biomarker and its significant impact on cardiovascular risk in a recent discussion with Dr. Steve Kopecky.In 'Lipoprotein (a) Elevation: What Does it Do to Increase CV Risk and What to Know About Treatment', the discussion dives into lipoprotein (a) and its significant implications on cardiovascular health, prompting us to explore its effects and current treatment options. Lipoprotein (a), often abbreviated as Lp(a), is closely associated with LDL cholesterol or "bad cholesterol". According to Dr. Vasile, about one in five people have elevated levels of Lp(a), which can independently predict serious cardiovascular events like heart attacks and strokes, regardless of other lipid levels. This makes understanding and managing Lp(a) essential for overall heart health. The Genetic Component of Lipoprotein (a) What's particularly concerning is that Lp(a) has a strong genetic basis, meaning if one of your parents has elevated Lp(a), you might be at risk as well. This trait is a bit complex – our bodies produce two different isoforms of Lp(a), making it difficult to predict levels based solely on family history. Dr. Vasile emphasizes the importance of screening for Lp(a), encouraging not just individuals with elevated levels, but also their first-degree relatives to undergo testing. By catching elevated Lp(a) levels early, we can encourage proactive management and potentially reduce cardiovascular risks for multiple generations. Current and Future Treatments Currently, impactful treatments specifically targeting Lp(a) are limited, though some emerging therapies are showing promise in clinical trials. For now, lifestyle modifications like maintaining a Mediterranean diet, regular aerobic exercise, and possibly low-dose aspirin can help mitigate cardiovascular risk associated with Lp(a) elevation, even if they don’t directly lower Lp(a) levels. The outlook is hopeful, as there are several new drugs in the pipeline aimed at effectively lowering Lp(a). If you have elevated Lp(a) levels or cardiovascular concerns, stay informed about these developments and engage with your healthcare provider regarding your risk factors. As we continue to learn more about biomarkers like Lp(a), emphasizing the importance of awareness and proactive healthcare is crucial for heart disease prevention. Remember, your heart health matters!

FDA's Rejection of Capricor Cell Therapy Raises Questions in Healthcare Innovation

Update The FDA's Tough Decision on Capricor's Cell Therapy In a significant move for the realm of innovative healthcare solutions, the FDA has recently denied the approval of Capricor Therapeutics' experimental cell therapy, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). This decision highlights the ongoing complexities in developing treatments for rare muscle diseases, where the stakes are high and patient needs are urgent. Understanding Duchenne Muscular Dystrophy and Heart Issues Duchenne muscular dystrophy is a severe genetic disorder predominantly affecting young boys, characterized by progressive muscle degeneration. Among the challenges faced by these patients is the development of heart complications, which can lead to heart failure. Deramiocel was designed to address these specific cardiac issues by harnessing the healing capabilities of cardiac cells. However, the FDA raised concerns regarding the therapy's efficacy and safety, prompting the question of how innovative solutions can meet regulatory standards while addressing critical patient needs. The Path Ahead for Capricor and Patients Despite the setback, Capricor remains committed to exploring further options to facilitate a successful treatment pathway for its patients. Healthcare IT professionals and digital health innovators might see this as a crucial moment to push the boundaries of technology in assessing clinical outcomes. In many cases like this, patient advocacy can play a pivotal role in shaping the future of treatment possibilities. How This Decision Impacts Digital Health Solutions This decision emphasizes the necessity for robust data and innovative technological integration in the healthcare industry. Digital health entrepreneurs are presented with a unique opportunity to support research and development in rare disease areas, enhancing the potential for successful therapies in the future. The intersection of technology and healthcare will be essential in paving the way for better patient outcomes as the medical landscape evolves.

New Proposal for Research Overhead Cuts: What It Means for Innovation

Update Understanding the Importance of Research Funding In recent weeks, academic organizations have come together to address significant changes proposed by the Trump administration regarding research funding cuts. These changes threaten to severely limit the financial resources available for essential research activities. The response from the Joint Associations Group (JAG), representing a coalition of 10 academic entities, is both timely and critical. A Dual Approach: Innovative Funding Solutions JAG has finalized a counterproposal offering two distinct methods to secure funding for research overhead payments. The first option involves institutions providing a comprehensive breakdown of their indirect costs within project grants. This approach aims at transparency and can ensure that necessary expenses are effectively accounted for, making it easier for funding bodies to understand the actual costs associated with research. The second option proposes a simplified method, allowing institutions to receive a fixed percentage of a project’s total budget. This alternative is designed to streamline the process, making it less burdensome for researchers and their organizations. By offering these two pathways, JAG seeks not only to preserve funding but also to maintain the integrity of research operations across the country. Why Stakeholders Should Pay Attention The outcomes of these funding discussions hold weight beyond university walls—they impact patient care, innovative medical discoveries, and the advancement of science as a whole. Given that academic institutions often serve as incubators for groundbreaking research, finding solutions that secure sufficient funding is essential for the progression of healthcare and medicine. The Road Ahead: Will It Meet Resistance? The next steps involve gauging the acceptance of this counterproposal by lawmakers and the administration. Given the immense implications, it’s crucial for stakeholders—including researchers, policymakers, and the public—to remain engaged in this dialogue. Active participation in advocacy efforts could influence the decision-making process significantly, ensuring that essential research continues unimpeded. A Call for Advocacy As discussions regarding research funding unfold, it is important for everyone to stay informed and involved. Engaging with local representatives about the importance of continued investment in research could be a powerful step towards safeguarding the future of scientific innovation. Your voice matters—join in advocating for the funding that supports the research that ultimately benefits us all.

Add Row
Add Element
Glytain Logo
update
WorldPulse News
cropper
update

Glytain empowers healthcare professionals and businesses to navigate the evolving digital landscape, driving innovation and improving patient outcomes. 🚀

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6
Add Element

+639220000000

AVAILABLE FROM 8AM - 5PM

City, State

, ,

Add Element

ABOUT US

At Glytain, we bridge the gap between healthcare and technology by delivering expert insights, cutting-edge trends, and in-depth analysis of digital health innovations. Our platform is designed for healthcare professionals, tech innovators, and forward-thinking businesses looking to stay ahead in the rapidly evolving healthcare landscape.

Add Element

© 2025 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*